Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL313182

Fc1cccc(CN(c2ccc3[nH]ncc3c2)C2CCNCC2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 16/20 0.71
SLC6A3 Q01959 16/20 0.71
SLC6A4 P31645 14/20 0.71
CHRM5 P08912 1/20 0.41
ROCK2 O75116 2/20 0.39
NPC1 O15118 1/20 0.39
DYRK3 O43781 1/20 0.39
MAP4K4 O95819 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CLK2 P49760 1/20 0.39
RAB9A P51151 1/20 0.39
CSNK2A1 P68400 1/20 0.39
ROCK1 Q13464 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PIM1 P11309 1/20 0.38
GSK3B P49841 1/20 0.38
AURKB Q96GD4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL27823451 0.93 SLC6A2 (0.83) SLC6A2SLC6A3SLC6A4CHRM5ROCK2
SCHEMBL312948 0.92 SLC6A2 (0.80) SLC6A2SLC6A3SLC6A4CHRM5ROCK2
Trifluoroacetic Acid SCHEMBL313722 0.88 SLC6A2 (0.66) SLC6A2SLC6A3SLC6A4CHRM5ROCK2
Trifluoroacetic Acid SCHEMBL313360 0.85 SLC6A2 (0.83) SLC6A2SLC6A3SLC6A4
SCHEMBL312413 0.84 SLC6A2 (1.00) SLC6A2SLC6A3SLC6A4ROCK2ROCK1
Trifluoroacetic Acid SCHEMBL314124 0.82 SLC6A2 (0.71) SLC6A2SLC6A3SLC6A4
SCHEMBL313212 0.78 SLC6A2 (0.77) SLC6A2SLC6A3SLC6A4ROCK2
Trifluoroacetic Acid SCHEMBL313960 0.78 SLC6A2 (0.82) SLC6A2SLC6A3SLC6A4
SCHEMBL312587 0.78 SLC6A2 (0.76) SLC6A2SLC6A3SLC6A4ROCK2ROCK1
Trifluoroacetic Acid SCHEMBL312982 0.76 SLC6A2 (0.70) SLC6A2SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093285-B2 Aminopiperidinyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-01-10 US disclosed
CN-101977904-A Aminopiperidinyl derivatives and uses thereof HOFFMANN LA ROCHE 2011-02-16 CN disclosed
EP-2268631-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009118254-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-10-01 WO disclosed
US-20090247568-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF ROCHE PALO ALTO LLC 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247568-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF MAOB, ADORA2B, HTR1B SLC6A2 8/4885SLC6A3 28/4885SLC6A4 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.